Malirid-DS Tablet contains Primaquine 15 mg, an antimalarial agent primarily used for the radical cure and prevention of relapses of Plasmodium vivax and Plasmodium ovale malaria. Primaquine acts by targeting the dormant liver stages (hypnozoites) of the parasite, thereby preventing relapse and ensuring complete eradication of the infection. It is also effective against gametocytes of Plasmodium falciparum, reducing transmission. Malirid-DS is indicated for use in combination with blood schizonticides in the treatment of malaria and for prophylaxis in individuals traveling to endemic areas. The tablet should be administered under medical supervision, with dosage adjusted according to the patient’s weight and clinical condition. Caution is advised in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia. Common adverse effects include gastrointestinal disturbances, headache, dizziness, and, rarely, methemoglobinemia. Primaquine is contraindicated in pregnancy and lactation unless the potential benefits outweigh the risks. Regular monitoring and adherence to prescribed regimens are essential to maximize therapeutic efficacy and minimize adverse effects. Malirid-DS Tablet is a vital component in comprehensive malaria management and prevention strategies.